NervGen Pharma Rings the Closing Bell

About This Event

NervGen Pharma (Nasdaq: NGEN), a clinical-stage biopharmaceutical company developing first-in-class neuroreparative therapeutics for spinal cord injury and other neurotraumatic and neurologic conditions, visits the Nasdaq MarketSite in Times Square.

In honor of the occasion, Adam Rogers, MD, Chief Executive Officer of NervGen Pharma rings the Closing Bell. 

Nasdaq Originals Exclusive insights on the forces shaping the convergence of technology, business and sports. Explore